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Abstract. Nanoparticles, microparticles, and other biomaterials are advantageous in vaccination
because these materials provide opportunities to modulate speciﬁc characteristics of immune
responses. This idea of “tuning” immune responses has recently been used to combat infectious
diseases and cancer, and to induce tolerance during organ transplants or autoimmune disease. Lymph
nodes and other secondary lymphoid organs such as the spleen play crucial roles in determining if
and how these responses develop following vaccination or immunotherapy. Thus, by manipulating the
local microenvironments within these immunological command centers, the nature of systemic
immune response can be controlled. This review provides recent examples that harness the
interactions between biomaterials and lymph nodes or other secondary lymphoid organs to generate
immunity or promote tolerance. These strategies draw on mechanical properties, surface chemistry,
stability, and targeting to alter the interactions of cells, signals, and vaccine components in lymph
nodes. While there are still many unanswered questions surrounding how best to design biomaterial-
based vaccines to promote speciﬁc structures or functions in lymph nodes, features such as controlled
release and targeting will help pave the way for the next generation of vaccines and immunotherapies
that generate immune responses tuned for speciﬁc applications.
KEY WORDS: autoimmunity and tolerance; biomaterials; immunology; nanoparticles and
microparticles; vaccine.
INTRODUCTION
Vaccination has produced one of the greatest impacts on
human health in history (1). No other breakthrough has
virtually eradicated fatal diseases like polio or small pox with
just a few doses. However, many diseases impacting public
health create complex challenges for existing vaccine and
immunotherapy strategies. For example, HIV evades clear-
ance by mutation and concealment in the mucosa, tumors
actively suppress tumor-destructive immune cells, and many
treatments for autoimmune disease lack speciﬁcity. To
address challenges such as these, new vaccines and immuno-
therapies will need to generate potent responses against
speciﬁc molecules—termed antigens—while also tuning the
characteristics of these responses to combat a target disease.
Lymph nodes (LNs) and the spleen are some of the key
structures that coordinate the type and speciﬁcity of these
responses.
In the last several years, the impact of nanoparticles
(NPs), microparticles (MPs), and other biomaterial vaccine
and immunotherapy carriers on LNs has been an intriguing
area of focus. These studies reveal the potential of
biomaterials to program the local LN microenvironment
to control systemic immune response. The broad potential
of biomaterials for vaccination and immunotherapy has
recently been reviewed (2–4). This paper focuses more
speciﬁcally on the interactions of biomaterials with LNs and
other immune tissues (e.g., spleen) during the generation of
stimulatory or regulatory immune responses. The discussion
begins with background describing how adaptive immune
responses are generated, with an emphasis on the active
role that LN tissues and resident cells play in these
processes. Key recent examples are then discussed to
demonstrate how biomaterials enhance the generation of
immunity, for example, against a foreign pathogen, or of
tolerance, such as to combat autoimmune disease. The
review concludes by identifying unanswered questions and
highlighting some of the ways in which answers to these
questions could inform new approaches to exploit the
interactions between biomaterials and LNs for vaccination,
immunotherapy, and tissue engineering.
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ADAPTIVE IMMUNITY REQUIRES STRUCTURED
INTERACTIONS BETWEEN IMMUNE CELLS
Antigens in Peripheral Tissue Must Reach LNs to Initiate
Adaptive Immune Response
The innate immune system is composed of ﬁrst-response
defense mechanisms including (i) skin that creates a physical
barrier against pathogens, (ii) immune cells that home to and
engulf pathogens or other immunogenic structures, and (iii)
receptors that detect broad classes of molecular patterns absent
in mammals but present in viruses and bacteria. In contrast,
adaptive immunity involves the generation of immune re-
sponses speciﬁc for a particular molecule, termed an antigen.
Generation and control of these antigen-speciﬁc responses
require complex interactions between immune cells, antigens,
and soluble factors in secondary lymphoid organs (SLOs) (5,6).
These tissues include the spleen, LNs, and Peyer’s patches. The
spleen samples circulating antigens present in blood, while
specialized nodules termed Peyer’s patches sample antigens in
mucosal tissues such as the small intestine.
LNs are found throughout the body, concentrating antigens
from a network of lymphatic vessels that continually sample tissue
for antigens or other immune signals (7,8). Soluble antigens with
molecular weights of ~70 kDa or with particle size between 20 and
50 nmpassively drain along the lymphatics, while larger antigens or
pathogens are phagocytosed and carried to these LNs by
specialized antigen-presenting cells (APCs) such as dendritic cells
(DCs) (Fig. 1a) (2,9). APCs continually survey tissue and blood for
inﬂammatory signals and antigens, which upon detection, stimulate
phagocytosis and a change in the expression of homing receptors
that allows antigen-experienced APCs to travel to nearby
“draining” LNs (7). In LNs, processed antigens are presented by
APCs to activate resident T and B lymphocytes. Activated
lymphocytes andmolecules secreted by these cells (e.g., antibodies)
exit LNs and search the periphery to immobilize or destroy the
pathogens against which they are armed in LNs. Thus, LNs are key
structures that vaccines and immunotherapies must reach to
generate antigen-speciﬁc responses that can combat pathogens
and diseased tissue located in other regions of the body.
LNs Contain Supportive Stromal Components, B Cell Zones,
and Regions Rich in APCs and T Cells
LNs are bean-shaped structures surrounded by a
collagen-rich ﬁbrous capsule (Fig. 1b). Antigens—in soluble
Fig. 1. Schematic overview of cell-mediated and antibody-mediated immunity relating to the LN. a Graphical depiction of
antigen drainage through lymphatics andAPC-aided transport to LNs. b Illustration of the LNmicroenvironment containing key
cells and stromal structures. c Activation of cytotoxic T cell is induced by DCs which process and present antigens with co-
stimulatory molecules to naive CD8+ T cells within the T cell zones of LNs. d B cell activation occurs after an activated CD4+
helper T cell binds to B cells presenting the same antigen at the periphery of the LN follicle. Activated B cells then migrate to
germinal centers (GCs) where proliferation, somatic mutation, and, with the help of follicular DCs and follicular helper T cells,
afﬁnity maturation occur. These processes result in plasma cells that exit the LN and secrete high-afﬁnity antibodies
324 Andorko et al.
form or phagocytosed within APCs—enter LNs via the
afferent lymphatic that drains lymph ﬂuid ﬂowing from
upstream lymphatic vessels (7,8). This ﬂuid travels around
the periphery via the subcapsular sinus (SCS), a region rich in
macrophages able to take up and process incoming antigen
or particles, and is dispersed throughout the LN by
supportive stromal tissues that include ﬁbroblastic reticular
cells (FRCs) and extracellular matrix (ECM) components
secreted by FRCs (5). This network of conduits and cells
ensures that small, soluble antigens can efﬁciently penetrate
deep into LNs.
DCs and T cells comprise an interior region of LNs
called the paracortex (“T cell zone”), while B cells and
specialized follicular dendritic cells (FDCs) make up a
surrounding cortex called the “B cell zone” (Fig. 1b)
(10,11). The degree of intermingling between these two
regions is controlled by soluble chemotactic factors called
chemokines. The chemokines CCL19 and CCL21 attract T
cells expressing CCR7 to the paracortex, while CXCL13
attracts B cells expressing CXCR5 to the follicles of the
cortex (10,11). During generation of adaptive immunity, this
balance changes: B cells upregulate CCR7 receptors for
CCL19/CCL21, while T cells upregulate CXCR5 receptors
for CXCL13, promoting interactions between APCs, T cells,
and B cells at the interface of the T and B cell zones. The
purpose of these interactions is to generate effector cells and
secreted antibody molecules speciﬁc for a particular antigen
encountered in organs, blood, or peripheral tissue. Upon
activation and expansion, T cells and B cells are collected and
exit the LN through the medulla and efferent lymphatic.
Structures called high endothelial venules (HEVs) also
connect LNs with circulatory vasculature, serving primarily
as a conduit for lymphocytes to travel between blood and
LNs. A summary of the key cells and structures of the LN can
be found in Table I.
Adaptive Immunity Requires Specific Interactions
Between APCs, T Cells, and B Cells in LNs
The major classes of adaptive responses include i) cell-
mediated immunity, through which cytotoxic T lymphocytes
directly destroy infected host cells, and ii) antibody-mediated
immunity, which involves binding, neutralization, and clear-
ance of antigens by circulating antibodies speciﬁc for these
pathogens. In the simplest sense, cell-mediated immunity
removes intracellular pathogens such as viruses, while anti-
bodies are able to address extracellular toxins and pathogens
(e.g., bacteria). Cell-mediated and antibody-mediated re-
sponses develop following the activation of naive, antigen-
speciﬁc T cells and B cells, respectively (12,13). These
processes involve interactions with APCs in LNs or other
SLOs. Naive CD8+ T cells are activated by DCs that have
encountered, processed, and are presenting the antigen these
T cells are speciﬁc for (i.e., a “cognate” antigen) (Fig. 1c).
Importantly, this activation requires that the cognate antigen
be presented by the APCs in a protein complex called major
histocompatibility complex I (MHC-I). Activation also
requires co-stimulatory surface molecules that are expressed
when DCs encounter inﬂammatory signals—often adjuvants
in the case of vaccines. These agents enable DCs to co-
present co-stimulatory signals to CD8+ T cells during antigen
presentation. This set of interactions causes CD8+ T cells to
expand and differentiate to cytotoxic T lymphocytes (CTLs)
that migrate from LNs to destroy host cells expressing the
target antigen (e.g., due to a viral infection). A similar process
occurs in DCs presenting antigen in MHC-II to CD4+ helper
Table I. Key Cells and Structures Comprising Lymph Nodes
Cell or tissue Acronym Key function
Professional antigen presenting cell APC Cells exhibiting a primary function of processing and presenting antigen. Key
populations include DCs, B cells, and macrophages.
Dendritic cell DC APCs surveying peripheral tissue for antigen. DCs take up antigen, migrate to LNs,
then present antigen to T and B cells to generate antigen-speciﬁc immunity.
T lymphocyte T cell Cells involved in direct cell killing of infected host cells (CD8+ cytotoxic T cell population)
and helper functions that support antibody production (CD4+ helper T cells).
B lymphocyte B cell Cells that differentiate to plasma cells that are able to secrete antibody molecules that
bind antigens. Binding leads to neutralization or destruction of these targets.
Fibroblastic reticular cell FRC Stromal cells that support trafﬁcking of soluble signals and antigen throughout LNs.
These cells also organize LN structure by secreting extracellular matrix components.
Follicular dendritic cell FDC Specialized dendritic cells able to capture and present antigen to B cells in GCs to
promote high-afﬁnity antibodies.
Capsule Dense layer of connective tissue that surrounds the internal structure of LNs.
Afferent lymphatics Entry of antigen and immune cells from lymphatics.
Efferent lymphatics Exit of immune cells from LNs to lymphatics.
Subcapsular sinus SCS Drains and distributes lymph throughout LNs.
Medulla Drains activated lymphocytes in LNs to efferent lymphatics for return to tissue and
blood.
High endothelial venule HEV Portal allowing exchange of lymphocytes with blood.
T lymphocyte zone (paracortex) Interior domain rich in T cells and DCs.
B lymphocyte zone (cortex) Follicular region located at the peripheries of the paracortex that is rich in B cells and
FDCs.
Germinal center GC Structures that form to co-mingle specialized DCs, helper T cells, and B cells during
induction of high-afﬁnity antibodies.
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T cells that play an important role in the activation of B cells
to produce antibodies.
B cell activation is initiated when B cells in the cortex
encounter their cognate antigen, altering the balance of
chemokine receptors on these cells and causing migration
toward the T cell zone (Fig. 1d). Simultaneously, helper CD4+
T cells with the same antigen speciﬁcity migrate toward the B
cell zone following activation by DCs. B cells are activated at
the edge of the cortex by these helper CD4+ T cells, then
move back into the cortex and proliferate to form a germinal
center (GC). In GCs, the afﬁnity of the proliferating B cell for
the cognate antigen is increased through interaction with
resident FDCs that deliver survival signals to B cells that
strongly bind antigens presented by FDCs. These processes
involve somatic mutation and afﬁnity maturation and are
detailed in recent reviews (14,15). The result of these events
is the differentiation of B cells to plasma cells that migrate to
the periphery and bone marrow to secrete high-afﬁnity,
antigen-speciﬁc antibodies that enter blood and peripheral
tissue.
The LN Microenvironment Actively Impacts the Development
of Immunity or Tolerance
One of the fascinating developments over the past
decade has been the realization that stromal components
of LNs and other SLOs not only serve a structural
function but also actively promote immunity or tolerance.
For example, in the absence of antigen and activating
signals, T and B cell zones are maintained in a segregated
arrangement (Fig. 2a) (16). In contrast, during generation
of adaptive immunity, the LN rearranges to promote
speciﬁc types and durations of interactions between APCs,
T cells, and B cells (Fig. 2b) (16). The FRC network and
other stromal components support interactions such as
these through production of ECM components, transport
of antigens and signaling molecules (e.g., chemokines and
cytokines), and establishment of conduits through which
lymphocytes travel. Recent studies also illustrate that
lymphocytes migrate toward discrete microdomains of
LNs during inﬂammation and immunity compared with
migration during tolerance. These effects also correlate
with upregulation and downregulation of speciﬁc stromal
components such as laminins (17). Thus, the combinations
of antigens and immune signals present in LNs, along with
the speciﬁc organization of these tissues, help determine
the types of immune responses that develop systemically.
Below, we discuss how biomaterials offer new ways to
control these parameters to promote stimulatory immune
responses (i.e., immunity), as well as to regulate or
redirect responses toward immune tolerance.
BIOMATERIALS EXHIBIT MATERIAL PROPERTIES
THAT ACTIVATE IMMUNE PATHWAYS
The physicochemical properties of biomaterials can act
as intrinsic immune signals that help shape immunity. Some
of the properties which have been studied along these
lines—reviewed in (2–4)—include molecular weight, surface
chemistry, and particle shape and size. This body of work
has demonstrated that biomaterial properties alter lymphat-
ic transport, DC uptake and activation, activation of
inﬂammatory pathways (e.g., toll-like receptors (TLRs)
and inﬂammasomes), and secretion of signaling proteins
called cytokines (9,18–31). For example, carriers such as
poly(lactic acid-co-glycolic acid) (PLGA) and polystyrene
have been shown to activate the immune system through
inﬂammasome signaling even in the absence of other
immune signals or adjuvants—agents added to vaccines to
enhance immune response (32–34). Since synthetic bioma-
terials such as PLGA or naturally occurring biomaterials
like chitosan are becoming ubiquitous in the design of
vaccine and immunotherapy carriers, understanding the link
between material properties and immune response could
Fig. 2. LN reorganization during generation of adaptive immune response. a A LN in a
resting state with distinct B cell and T cell zones. b After activation with antigen and a
strong adjuvant (complete Freund’s adjuvant), the LN microenvironment rearranges to
promote intermingling of B cell and T cell zones and formation of GCs. Adapted with
permission (16)
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allow more rational design of materials that serve not only
as carriers but also as agents that actively “tune” immune
responses to combat infectious disease, cancer, or autoim-
munity. Thus, this review focuses on the impact of
biomaterials on LN organization and function to promote
immunity or to regulate immune response (tolerance).
Emphasis is also placed on highlighting new approaches
reported in the last several years. Table II summarizes the
examples presented below that investigate NPs and other
biomaterial-based vaccines to help control the structure and
function of LNs and other SLOs.
THE INTERACTIONS OF BIOMATERIALS IN LNs
CAN BE EXPLOITED TO ENHANCE IMMUNITY
Biomaterials provide a unique platform for vaccination
and immunotherapy. Interestingly, these materials can mimic
some features of clinically approved adjuvants (e.g., alum),
for example, by condensing or encapsulating antigen or other
immune signals into particulate structures with sizes ranging
from tens of nanometers to several microns. This size range
allows efﬁcient uptake by APCs. Biomaterials can also be
used to passively or actively target immune tissues such as
LNs. Lastly, these materials allow co-delivery of multiple
cargos (e.g., antigen, adjuvant, and drug) and controlled
release of vaccine and immunotherapy components. This
last feature of co-delivery is becoming increasingly impor-
tant in modulating the types of responses that are
generated for a speciﬁc vaccine or therapy. The sections
below will provide speciﬁc examples of how these proper-
ties are being harnessed to enhance “traditional” immune
responses aimed at arming the body to destroy infectious
pathogens or cancer.
Particle Size Helps Determine the Trafficking and Retention
of Biomaterials in LNs
Both traditional (i.e., soluble) and biomaterial-based
vaccine components must reach LNs to generate adaptive
immune responses. Several groups have carefully con-
trolled the size of NPs and other vaccine carriers to
passively target LNs and the DCs residing in these
tissues. For example, by altering particle size, the
effectiveness of drainage through the lymphatics and the
retention time within LNs can be changed. In studies
conducted by Reddy et al., poly(propylene sulﬁde) NPs
with deﬁned sizes were injected intradermally into the tail
of mice and the particle drainage through the lymphatics
Table II. Examples Demonstrating the Impact of Biomaterials on Lymph Nodes
Setting Biomaterial Functional impact on lymph nodes Reference
Immunity Poly(lactic acid-co-glycolic acid) (PLGA)
and polystyrene
Inﬂammasome activation and increase in IL-1β secretion (32,33)
Immunity Chitosan/heparin Increase in GC formation compared to soluble formulations (45)
Immunity Pluronic-stabilized poly(propylene sulﬁde) Targeting of tumor-draining LN; delivery of vaccines overcame
immunosuppressive tumor environment by activating DCs and
increasing the CD8+ T cells to TREG ratio
(49,50)
Immunity Lipid vesicles and micelles Effective drainage to LN sinuses and increased uptake by APCs
leading to increased antigen speciﬁcity and cytokine secretion
(28)
Immunity ICMVs Trafﬁcking to LN-resident macrophages and DCs in SCS; induces
GC formation resulting in long lasting, high-avidity antibodies
(41–43)
Immunity PLGA Adjuvant-loaded NPs synergistically increase antibody-mediated
immunity through creation of GCs and high-avidity antibodies
(44)
Immunity Lipid stabilized PLGA Increased antigen speciﬁc CTLs and antibody production caused
by local depot effect in LNs
(53,54)
Tolerance PLGA Trafﬁcked to LNs; preferential uptake by macrophages and DCs;
increases DC activation and CD4+ helper T cell proliferation;
upregulation of PD-L1; induction of antigen-speciﬁc FoxP3+ T cells
(4,40,70,84,85,89)
Tolerance Liposomes Uptake by LN-resident APCs leading to expansion of TREGS
speciﬁc for self-antigens included in liposomes
(71)
Tolerance Iron oxide Expansion of low-avidity TREGS in and around LNs that suppress
antigen presentation by APCs and directly kill APCs
(73)
Tolerance Polystyrene beads Support antigen presentation to DCs leading to inactivation of
antigen-speciﬁc CD4+ T-cells; reduction of CD4+ and CD45+ cell
inﬁltration into CNS; reduction in antigen-speciﬁc inﬂammatory T
cell proliferation
(80)
Tolerance Poly(ethyleneimine) Trafﬁcking to follicular and marginal zones of LNs; promotes
interactions between DCs and T cells with regulatory characteristics
(86)
Tolerance Poly(ethylene glycol) and poly(lactide) DCs and T cells modiﬁed by particles drain to LNs, reducing the
number and proliferative capacity of effector T cells; increase
TREGS in LNs; decrease IFN-γ-producing cells
(87–89)
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to LNs was monitored (9,35). Twenty- and 45-nm particles
drained effectively through lymphatic vessels to the LNs,
while 100-nm particles largely remained at the injection
site. Additionally, 20-nm particles were preferentially
taken up by LN-resident macrophages and DCs. These
particles were also retained in LNs for more than 4 days
(35). A related study demonstrated that the surface
chemistry of NPs altered DC activation and antigen-
speciﬁc T cell responses in LNs, underscoring the idea
that both physical and chemical properties of materials
play a role in skewing immune function (9).
The route of injection also helps deﬁne if and how
NPs of a given size will reach LNs. For example, injection
of 90 nm virus-like particles via multiple different
injection routes (e.g., subcutaneous, intraperitoneal, intra-
muscular, and intradermal) resulted in unique particle
drainage patterns to the inguinal, lumbar, popliteal, and
sciatic LNs (36). Notably, intradermal injections resulted
in NPs localized in the SCS of the sciatic and popliteal
LNs, supporting the hypothesis that these relatively small
diameter NPs were transported via lymphatic vessels to
the LNs. As opposed to larger particles trafﬁcked to LNs
by APCs, these smaller particles drain freely to the LNs
through the afferent lymphatics and can then be scav-
enged by SCS-resident APCs (e.g., macrophages). Thus,
by controlling the injection route and size of NPs or MPs,
the domains that these materials reach in LNs can be
controlled. This strategy provides a route to design
vaccines that speciﬁcally target APCs within LNs for
phagocytosis or that are small enough to penetrate deeper
into other domains (e.g., T cell zone).
Though there are only a handful of approved—or nearly
approved—adjuvants in the USA and European Union
developed over the last century, in a sense, these agents are
the original biomaterial-based vaccine components. One of
the most widely used is aluminum salts (alum), and others
include emulsions (MF59 and AS03), liposomes (AS01), and
synthetic DNA and RNA sequences (polyI:C and CpG).
Though there is still some debate as to the mechanism by
which alum or other adjuvants enhance vaccination, these
materials often persist at the injection site to serve as a depot
(i.e., “controlled” antigen release) and increase antigen
phagocytosis and presentation that enhances DC activation
(37). In a direct comparison of alum with poly(lactic acid)
(PLA) MPs, intramuscular immunization with either PLA or
alum promoted antigen-speciﬁc antibodies. Interestingly,
PLA MPs increased expression of MHC-I and MHC-II
molecules on DCs, while alum only increased MHC-II
expression (34). This ﬁnding suggests that particle-based
vaccines may generally enhance antigen cross-presentation—a
process by which DCs can present phagocytized antigens in
MHC-I molecules to enhance CD8+ T cell-mediated adaptive
response instead of MHC-II molecules which is the traditional
route for phagocytized antigens. In addition to particle size,
recent studies have investigated the role that the geometry of
vaccine carriers plays in immunogenicity. These studies demon-
strate that the shape and aspect ratio of synthetic carriers play an
important role in modulating T cell activation (29). Thus, future
vaccines could combine the rational selection of properties such
as size or shape with targeting or controlled release of multiple
antigens, adjuvants, or immune signals.
Molecular Markers Can Be Used to Effectively Target
LN-Resident Cells
In addition to passive targeting by size, LNs and LN-
resident cells are being actively targeted by conjugating NPs and
MPswith speciﬁc ligands or receptors. One of themolecules that
has been targeted is DEC-205 (CD205), a transmembrane
protein found primarily on DCs. Monoclonal antibodies speciﬁc
to DEC-205 have been used to decorate acid-degradable
polymer and liposome vaccines loaded with model antigens
(e.g., SIINFEKL from ovalbumin) and B16-melanoma antigens
(38,39). Treatment of mice with anti-DEC-205 particles in-
creased the amount of vaccine present in DCs residing in the
inguinal LN following subcutaneous immunization and in the
popliteal LN following a footpad injection. When administered
with LPS or interferon gamma (IFN-γ) to activate DCs, this
increase in vaccine accumulation in the LNs correlated to
increases in splenic cytotoxic T lymphocytes. Following an
intravenous melanoma challenge, the number of tumors in the
lungs decreased in mice treated with anti-DEC-205 particles
compared to control particles conjugated to an irrelevant
targeting peptide. This approach demonstrates the promise of
actively targeting biomaterials to speciﬁc LN-resident popula-
tions to enhance systemic adaptive immune responses.
Liu et al. recently used albumin as a shuttle to direct lipid-
based vaccines to LNs (28). Albumin is a serum protein that
serves to transport fatty acids from the blood into lymphatics
and to LNs. To exploit this pathway, lipids containing an
albumin binding domain made from a diacyl tail were conjugat-
ed to peptide antigens and CpG—a TLR9 agonist that activates
TLR pathways triggered by non-mammalian DNA (e.g., from
bacteria) (Fig. 3a). Thesematerials are able to self-assemble into
micelles when placed in aqueous solution due to the hydropho-
bic diacyl lipid tail. Following subcutaneous injections in mice,
albumin-targeted micelles efﬁciently drained to axillary and
inguinal LNs, while formulations with low albumin-binding
domains were not effectively trafﬁcked to LNs. Interestingly, by
altering the length of a polyethylene glycol (PEG) spacer or
increasing the number of carbons in the lipid backbone, vaccine
accumulation in the draining LNs could be controlled (Fig. 3b)
(28). Mechanistic studies revealed that micelle stability played a
crucial role in how these materials were trafﬁcked to LNs.
Micelles were stabilized with guanine repeat units. Stabilization
with four or more guanine repeats (Lipo-G4-CpG) did not
support trafﬁcking of micelles to LNs, whereas reversible (i.e.,
non-stabilized) micelles assembled with zero or two guanine
repeats (Lipo-CpG and Lipo-G2-CpG, respectively) reached
LNs and were co-localized with macrophages and DCs (Fig. 3c).
The dependence of LN trafﬁcking on structure suggests that in
themicelle form, albumin is unable to access the binding domain
(diacyl lipid tail), preventing albumin-mediated trafﬁcking to
LNs. Building on these ﬁndings of increased accumulation and
retention time of the albumin-binding micelle vaccines in LNs,
peptides speciﬁc to HPV-derived cervical cancer or melanoma
were added to these structures and used to immunize mice after
tumor inoculation. In both of these disease settings, a striking
increase in antigen-speciﬁc CD8+ T cells and functional
inﬂammatory cytokines (IFN-γ and tumor necrosis factor
alpha (TNF-α)) was observed, resulting in tumor regression
and prolonged survival in immunized mice. These highly
promising outcomes are fundamentally a result of the higher
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concentrations (targeting) and retention (exposure time) in
LNs, important characteristics that motivate the discussion
below on the role that duration and concentration of antigen
and immune signals in LNs play in driving immunity.
The Kinetics and Concentration of Antigen Delivery in LNs
Can Be Exploited to Enhance Immunity
An intriguing study by Johansen et al. demonstrated that
concentration and duration by which antigens, adjuvants, and
immune signals reach LNs are just as important as how
efﬁciently these signals reach LNs. In these studies, mice were
immunized subcutaneously with soluble antigen and adjuvant
using well-deﬁned doses and injection regimens: (i) one bolus
dose, (ii) regularly spaced, equivalent doses, (iii) regular
injections with exponentially decreasing doses, or (iv) regular
injections with exponentially increasing doses (Fig. 4a). Across
all of these regimens, only mice receiving exponentially
increasing doses exhibited signiﬁcantly increased IFN-γ secre-
tion by CD8+ T cells (Fig. 4b). Functionally, this effect
signiﬁcantly enhanced antiviral response upon a viral challenge
with lymphocytic choriomeningitis virus (40). These results
suggest that the persistence and accumulation of antigen and
inﬂammatory signals is important in inducing effective adaptive
immune responses. For this reason, the controlled release
properties of biomaterials are, and have been, of great interest
for vaccine and immunotherapy applications. As illustrated by
several of the examples highlighted in the following sections,
these approaches hold great potential to direct response, while
also reducing the burden on patients through decreasing the
number or frequency of injections and treatments.
Biomaterials Carry Immune Signals to LNs to Promote
Changes in LN Structure and Function
As alluded to above, NPs, MPs, and other biomaterials
offer a unique opportunity to alter local LN structure, and
subsequently, systemic immunity by delivering combinations
of antigens and adjuvants. This approach has recently been
exploited to enhance antibody-mediated immunity by pro-
moting GC creation. These microdomains are required for
activation and differentiation of B cells into plasma cells that
secrete high-afﬁnity antibodies targeting a speciﬁc pathogen.
One promising example of this strategy is the synthesis of NPs
from interbilayer-crosslinked multilamellar vesicles (ICMVs)
(41–43). ICMVs are synthesized by fusing liposomes using
divalent cations to form multilamellar vesicles, then
crosslinking and PEGylating these structures into 100–300-
nm particles. ICMVs have been loaded with a range of
vaccine cargos including model antigens (ovalbumin (OVA)),
helper T cell peptides, and antigens for malaria and simian
immunodeﬁciency virus (SIV) gag. Following subcutaneous
Fig. 3. Trafﬁcking of lipid-based vaccines depends on material properties. a Schematic of amphiphile
structure containing an albumin-binding domain, PEG spacer, and peptide antigen. b Excised LNs of mice
imaged by IVIS 24 h after treatment with ﬂuorescent amphiphiles with increasing PEG spacer length. c
Immunohistochemical staining of inguinal LNs following treatment with micelles with varying amounts of
guanine repeats. CpG (green), T cells (CD3, blue), B cells (B220, pink). Adapted with permission (28)
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immunization in mice, ICMVs are retained in the draining LN
for over 2 weeks and co-localized with macrophages and DCs
of the SCS, suggesting that both drainage via lymphatics and
transport after APC phagocytosis contribute to ICMVs
trafﬁcking to LNs (41). Importantly, immunization with
ICMVs increases the number of GCs in the draining LNs
compared to soluble vaccine formulations (Fig. 5a) (41).
These structures dramatically enhance cell- and antibody-
mediated immunity by increasing antigen-speciﬁc CD8+ T
cells and antigen-speciﬁc serum antibody levels, respectively.
Mice immunized and boosted subcutaneously with ICMV
formulations loaded with malaria antigens (VMP-ICMV)
generated high levels of malaria-targeted antibodies com-
pared to vaccination with alum as an adjuvant. Strikingly, this
effect persisted for more than 400 days after inoculation (41).
Since GC formation is integral for high-afﬁnity antibody
production and strong humoral immune responses, continued
development of materials that promote these structures may
be particularly advantageous for parasitic diseases (e.g.,
malaria) which involve extracellular pathogens that could be
bound or neutralized by antibodies. Thus, understanding the
link between biomaterial features that are trafﬁcked to
particular domains (e.g., SCS and B cell follicles) or support
speciﬁc interactions or microdomain formation (e.g., GCs) is
an important avenue for future research.
Several other approaches using conventional or
biomaterial-based vaccines have sought to induce GCs by
delivery of multiple adjuvants or TLR agonists. The
Pulendran lab has studied the effect of NPs loaded with
multiple TLRs in individual particles compared with co-
loading these signals in the same particle (44). In these
studies, GC formation was strongly dependent on the particle
loading scheme used to deliver the TLR agonists. Compared
with alum, PLGA NPs loaded with OVA and TLR4 agonist
Fig. 4. Immune signal kinetics and concentration in LNs controls immunity. a Subcutaneous dosing
schedule of mice with antigen (gp33) and adjuvant (CpG). b IFN-γ production of CD8+ T cells 8 days
after vaccination with the schedule seen in a and restimulation of lymphocytes with gp33. Adapted
with permission (40)
Fig. 5. Biomaterial vaccines can enhance GC formation and antibody avidity. a Confocal micrograph showing GC formation
in draining LN 2 weeks after subcutaneous injection of ICMVs. B cells (red, B220), ICMV (blue), GC (green, GL-7). b
Hemagglutinin (HA)-binding afﬁnity of serum-derived antibodies from mice immunized with biomaterial vaccine
formulations 28 days earlier. c 28 days after immunization, draining LNs were excised and stained for GC formation. GC
(red, GL-7), B cells (blue, B220), IgG (green). a Adapted with permission (41). b, c Adapted with permission (44)
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(MPL) or loaded with OVA and TLR7 agonist (R837)
increased GC formation in the LNs of mice following
subcutaneous injection. Strikingly, mice treated with particles
loaded with antigen, along with both TLR4 and TLR7
agonists exhibited a synergistic increase in GCs that also
increased the avidity of antibodies (Fig. 5b, c) (44). TLR4 and
TLR7 pathways detect bacterial polysaccharides and viral
RNA, respectively. Thus, triggering both of these pathways
may enhance B cell (TLR4) and T cell (TLR7) activation, as
well as generally increase DC functions such as antigen
presentation and co-stimulation. The effects of this more
robust activation of immune pathways may help inform the
design of future materials that contain multiple immune cues.
Recently, vaccines composed of chitosan and heparin
have been used to mimic specialized molecules called
granules (45). Granules are stable particles secreted by
specialized immune cells (mast cells) in response to a range
of stimuli that can include pathogen recognition. These
particles contain pro-inﬂammatory cytokines such as TNF-α
that promote local inﬂammation. Following footpad immuni-
zation with antigen-loaded NPs designed to mimic granules,
NPs localized to the SCS in LNs of mice and increased the
number of GCs. The resulting enhancement of antibody-
mediated immunity increased the survival of mice during a
lethal ﬂu challenge. Interestingly, empty particles without
cytokines also caused a modest increase in GCs (45). This
effect emphasizes the theme that biomaterials can enhance
immunity through targeting, co-delivery, and controlled
release of cargo, as well as through stimulatory pathways
activated by the structural features of these materials.
NP Vaccines Can Break Tumor Tolerance Through Local
Changes in Tumor-Draining LNs
The examples highlighted thus far share the aim of
generating effective immune responses against foreign path-
ogens. However, another prominent goal of biomaterial-
based vaccines and immunotherapies is centered on treating
cancer. Cancer cells and the tumor microenvironment exhibit
a number of characteristics that hinder the ability of the
immune system to ﬁght cancer (46). Notably, effective
treatments must generate robust responses against antigens
overexpressed on tumors, allow efﬁcient homing of immune
cells to tumors, maintain the function of tumor-primed
immune cells in the immunosuppressive tumor environment,
and generate tumor-speciﬁc memory cells that quickly
destroy nascent tumor cells to prevent relapse. This is a
daunting set of challenges, but combination therapies leverag-
ing biomaterials and the immune system offer many features
that could help address these hurdles. Kwong et al. have
created liposomes containing both a PEG/CpG lipid that was
conjugated via lipid insertion and anti-CD40 antibodies that
were added via maleimide chemistry. When these materials
are injected into solid tumors, the liposomes drain to nearby
LNs and remain in LN sinuses (47). This persistence causes a
local adjuvant effect in LNs for at least 48 h that allowed for a
majority of LN-resident APCs (DCs and macrophages) to
uptake the particles containing CpG, resulting in prolonged
survival of mice during tumor challenge compared to PBS
controls. Soluble treatments caused a bimodal effect of
increasing survival in some mice compared to liposomes and
causing earlier death in others, while liposomal delivery
reduced systemic toxicity by decreasing adverse side effects
such as weight loss and inﬂammatory cytokines (IL-6) in
blood (47).
Stephan et al. approached cancer immunotherapy with
biomaterials by modifying the surface of T cells with liposomes
or polymeric NPs loaded with cytokines or adjuvants (48). This
approach employed biocompatible thiol chemistry to conjugate
thesematerials to cells without altering key Tcell functions (e.g.,
proliferation and antigen recognition). Importantly, tumor-
speciﬁc CD8+ T cells modiﬁed with NPs then injected into
mice maintained the ability to home to tumor cells, carrying
particles and cargo to these sites. This unique approach allowed
efﬁcient delivery of cytokine-loaded NPs to melanoma tumors
and resulted in rapid proliferation of tumor-speciﬁc CD8+ Tcells
in LNs. Mechanistically, T cells conjugated with NPs polarized
CD8+ Tcells toward a central memory phenotype which is more
effective at breaking tumor immunosuppression. Thus, mice
treated with these tumor-speciﬁc T cells modiﬁed with NPs
eradicated tumors, while untreated mice and mice treated with
soluble drugs and T cells all succumbed.
Jeanbart et al. recently exploited preferential drainage of
30 nm poly(propylene sulﬁde) (PPS) NPs in tumor-draining
LNs and distal LNs (i.e., non-draining) for cancer therapy
(49). This work revealed that tumor-draining LNs were
enlarged compared to distal LNs. DCs and CD8+ T cells in
tumor-draining LNs also expressed high levels of PD-L1 and
PD-1, respectively. Binding of PD-1 on CD8+ T cells to the
cognate ligand (PD-L1 on APCs) negatively regulates T cell
proliferation and pro-inﬂammatory cytokine secretion, lead-
ing to suppression of T cell function. This suppression
supports tumor growth during cancer. In these studies, it
was shown that while the tumor-draining LN was immuno-
suppressed, these tissues also contained more antigen-speciﬁc
T cells, likely due to the proximity to the tumor (49).
Building on this observation, PPS NPs were conjugated
with CpG and mixed with antigen-loaded NPs, then injected
intradermally into the footpads of mice. NPs containing CpG
and tumor antigen (TRP2) or a model antigen (OVA) were
injected in the footpad on the same side as tumor induction.
This approach resulted in targeting of NPs to the tumor-
draining LN. Mice treated in this manner with NPs containing
CpG and TRP2 or OVA reduced tumor growth in a
melanoma model and in an OVA-expressing lymphoma
model. These improvements correlated with an increase in
CD8+ T cells speciﬁc for the corresponding antigens.
Targeting the tumor-draining LN also led to a decrease in
the number of immunosuppressive cells (e.g., regulatory T
cells (TREGS)) compared with mice injected on another limb
to target the non-tumor-draining LN (49). A related study
employed similar NPs co-loaded with CpG and Paclitaxel—a
powerful chemotherapeutic—to create a multifunctional can-
cer therapy (50). Together, these studies highlight the impact
of local delivery on efﬁcacy, with particles reaching tumor-
draining LNs providing a signiﬁcantly improved outcome
compared with particles targeted to non-draining LNs.
As discussed earlier, once NPs reach LNs, there are also
opportunities to direct immunity by delivering multiple
signals or by controlling the release of antigens, adjuvants,
and other signals. Below, new direct approaches to achieve
LN delivery are discussed.
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Intralymphatic Injection Allows Direct Targeting and Local
Engineering of the LN Environment
Building on the idea that the kinetics and combinations of
immune signals delivered to LNs play an integral role in the
development of cell-mediated and antibody-mediated immunity, an
intriguing area of fundamental and clinical research has focused on
direct injection of vaccines to LNs. In humans, intra-LN (i.LN.)
injection generally involves injection of soluble vaccine components
to LNs using ultrasound guidance, whereas preclinical studies in
mice utilize tracer dyes or surgical procedures to access the LN for
injection (51–54). Several important papers from the Kündig lab
describe clinical trials demonstrating that i.LN. injection can safely
promote tolerance to allergenswhile dramatically reducing both the
cumulative treatment dose and the treatment time (52,55). These
fundamental discoveries support the use of i.LN. delivery as a route
for generating potent immune response with staggeringly small
doses. This approach is particularly attractive for therapeutic
applications and has nucleated a number of additional recent and
ongoing clinical trials for chronic conditions, cancer, and allergies
(40,51,52,56–64). For example, patients immunized i.LN. with a
vaccine against grass pollen became tolerized after 3 injections over
8 weeks compared to 54 injections over 3 years when treated with
subcutaneous immunization (52). Strikingly, the overall dose
needed to evoke this tolerance was more than 1000× lower using
i.LN. injections compared with conventional vaccination routes. In
a similar study, tolerance to a cat dander allergenwas achieved after
3 i.LN. injections and this tolerance persisted for more than 300
days (55). While i.LN. injection is less suited for widespread
prophylactic vaccination, this is an intriguing idea for therapeutic
vaccines and immunotherapies that rely on delivery of several
vaccine components to LNs. However, many of these approaches
employ multiple injections or multiple cycles of injections to
increase the frequency or duration of exposure to antigen. Thus,
coupling i.LN. injectionwith biomaterials could further enhance the
performance of new therapeutic vaccines and immunotherapies
while reducing the dose, number, or frequency of injections.
Along these lines, Mohanan et al. tested the delivery of
common particle formulations (e.g., liposomes and NPs) along
intradermal, intramuscular, subcutaneous, and i.LN. routes. The
response toparticles ladenwithOVAantigenorOVAandadjuvants
was then assessed by antibody titers and cytokine secretion across
injection routes. Formulations injected i.LN. resulted in the
highest antigen-speciﬁc IgG2a antibody titers regardless of
whether or not a TLR agonist (CpG, TLR9) was present in
particles. This approach also increased the secretion of INF-γ
from splenocytes in the presence and absence of adjuvants (65).
Jewell et al. developed a non-surgical route for enhancing
cell-mediated and antibody-mediated immunity by i.LN. injec-
tion of lipid-stabilized polymer particles loaded with adjuvant
(53,54). In this study, lipid-coated NPs or MPs loaded with the
TLR3 agonist poly(inosinic:cytidylic acid) (polyIC) were
injected with OVA antigen into the muscle or into the inguinal
LNs of mice (Fig. 6a). MP formulations were retained in the LN
Fig. 6. MP depots promote cell-mediated and antibody-mediated immunity after i.LN. injection. a
Representative image of inguinal LN following i.LN. injection of ﬂuorescent MPs. B cells (blue, B220), T
cells (red, CD3), MPs (green). b PolyIC signal measured in vivo (top) and histological sections of excised
LNs (bottom) showing PolyIC signal 24 and 96 h after i.LN. injection. c OVA-tetramer staining showing
percent of blood CD8+ cells speciﬁc to OVA 7 days after intramuscular or i.LN. injections. d OVA-speciﬁc
IgG serum titers after intramuscular and i.LN. immunization with soluble or MP formulations. Adapted
with permission (53)
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as “depots” for at least 4 days, while soluble vaccine formula-
tions were quickly cleared. The increased retention of MPs also
controlled release and drove accumulation of polyIC within the
LN and in LN-resident APCs, resulting in more enduring
activation of DCs (Fig. 6b) (53). These effects potently
expanded antigen-speciﬁc CD8+ T cells circulating in
blood 1 week after a single i.LN. injection, an effect that
was not observed with soluble vaccine formulations (Fig.
6c). Mice immunized with MPs developed strong antibody
responses (Fig. 6d), demonstrating promotion of both cell-
mediated and antibody-mediated immune responses. CD8+
T cells from MP-immunized mice also exhibited larger,
more robust cytokine secretion, and all of these trends
persisted for at least 6 weeks without boosting. Interest-
ingly, NPs also increased the number of antigen-speciﬁc
CD8+ T cells and the level of cytokines secreted from
these cells compared with soluble vaccines, but at levels
lower than those observed in mice vaccinated with MPs
(53). This effect was a function of vaccine retention in
LNs, with NPs exhibiting a retention time intermediate
between the quick-draining soluble formulations and the
well-retained MP vaccine depots. Thus, delivery of con-
trolled release depots in LNs mimics the accumulating
dosing schemes discussed earlier (Fig. 3a) for soluble
vaccines and with i.LN. clinical trials, but with fewer or
less frequent injections (40). Such approaches could also
help ensure that each component of multifunction vac-
cines reaches LNs with the correct combinations, doses, or
release kinetics.
BIOMATERIALS CAN ALTER LN FUNCTION
TO PROMOTE IMMUNE TOLERANCE
The examples discussed thus far have used biomaterials
to promote stimulatory or inﬂammatory immune responses
for vaccination against pathogens or cancer. However, in the
past few years, enormous progress has been made in
harnessing biomaterials to regulate dysfunctional or unwant-
ed immune reactions. Many of these detrimental reactions
occur in autoimmune diseases such as multiple sclerosis,
diabetes, rheumatoid arthritis, and lupus, as well as in the
rejection of tissue grafts and organ transplants. In multiple
sclerosis, for example, myelin—the protein that insulates
neurons in the central nervous system (CNS)—is incorrectly
recognized as foreign by lymphocytes and antibodies (66–68).
This recognition leads to inﬁltration of these cells and
molecules into the CNS, resulting in inﬂammation and
destruction of myelin, and ultimately, neurologic decline. As
with the generation of immunity against foreign antigens in
healthy individuals, T cells and antibody-producing B cells
recognizing self-antigens are also expanded in LNs by APCs
presenting these self-molecules. Thus, biomaterials have
recently been applied to autoimmunity to stop these reactions
by destroying (deletion) or inactivating (anergy) pathogenic
cells, or by expanding specialized TREGS which are able to
suppress lymphocytes reactive against self-molecules such as
myelin. Broadly speaking, these regulatory mechanisms all
contribute to immune “tolerance,” a state in which the
immune system does not attack, or no longer attacks, a
particular peptide, protein, or cell type. One of the greatest
challenges facing new therapies for autoimmunity is the
induction of self-antigen-speciﬁc tolerance that prevents
harmful self-reactions without impairing the rest of the
immune system. This side effect is a persistent problem
with many of the drugs currently used to treat patients
with autoimmune disorders: lifelong treatment regimens
with broad immunosuppressants are vital to manage
disease but cause patients to be immunocompromised. In
this section, we will highlight some of the ways in which
the interactions between biomaterials and LNs or LN-
resident cells are being harnessed to promote tolerance.
While the discussion below is focused on the connection
between biomaterials and LNs to promote tolerance,
several recent reviews provide additional perspective on
opportunities to apply biomaterials to autoimmune diseases
and tolerance (2,4,69).
Particles Can Carry Regulatory Signals to LNs to Alter
the Interactions of APCs and Lymphocytes
One of the most fundamental ways in which biomate-
rials can be harnessed to promote tolerance is as a carrier
of drugs or other immune signals to LNs or other
immunological sites (70–79). In LNs, these cargos can
inﬂuence the interactions and functions of LN-resident cells
in similar ways to those exploited to promote stimulatory
responses or immunity. PLGA NPs for example have been
loaded with mycophenolic acid (MPA), an immunosuppres-
sant used in transplants (70). Systemic injection of these
particles resulted in drainage to the spleen and LNs, where
particles were preferentially taken up by macrophages and
DCs. During transplant studies, APCs in the LNs of mice
treated with particles exhibited elevated levels of PD-L1
(inhibitory ligand) that limited the ability of APCs to prime
T cells reactive against antigens expressed on the tissue
grafts. Thus, MPA-loaded particles draining to LNs deliv-
ered signals that impaired the ability of APCs to expand
graft/self-reactive T cells, resulting in tolerance that im-
proved graft survival (70).
The ability of biomaterials to co-deliver multiple cargos
has also been exploited to regulate the function of APCs in
LNs. In these studies, liposomes were loaded with a self-
antigen that is recognized as foreign in mouse models of
arthritis, along with a small molecule inhibitor of NF-κB, a
protein complex that controls inﬂammation and that is
overexpressed in many chronic inﬂammatory diseases (i.e.,
arthritis) (71). Uptake of liposomes by LN-resident APCs
reduced NF-κB levels and the proliferation of self-reactive
T cells, leading to reduced severity of arthritis. These
effects were achieved in part through the expansion of
TREGS in mice treated with the liposomes (71). Impor-
tantly, the TREGS generated in this study were speciﬁc for
the self-antigens included in the liposomes, emphasizing
the goal stated earlier: inducing tolerance against speciﬁc
self-antigens, without broad suppression of normal im-
mune functions.
One intriguing approach being developed to promote
antigen-speciﬁc tolerance is based on design of NPs decorated
with complexes of self-antigen loaded in MHC molecules
(73). As discussed earlier, MHCs are the complexes APCs
load antigens into for presentation to lymphocytes, along with
co-stimulatory signals. Presentation of antigen in MHCs
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without co-stimulation can cause T cells to become inactive or
promote regulatory functions. In this study, iron oxide NPs
were functionalized with complexes of MHC and self-
antigens associated with disease in type 1 diabetes (T1D),
without co-stimulatory signals (73). Treatment of prediabetic
or diabetic mice with NPs resulted in expansion of a pool of
low avidity (i.e., weakly binding) regulatory T cells in and
around LNs near the pancreas—the organ destroyed by self-
reactive immune cells in diabetes. These cells suppressed
antigen presentation by APCs in these LNs, as well as
exhibited direct APC killing in the pancreatic LNs (PLN)
compared with LNs remote from the pancreas (MLN) (Fig.
7a) (73). The decrease in APC numbers and activation levels
prevented expansion of self-reactive T cells that otherwise
could have migrated to and attacked the pancreas. The effects
of this treatment were striking, maintaining and restoring
control of blood glucose in mouse models of T1D when mice
were treated with MHC/NP complexes loaded with T1D
antigens, but not when mice were treated with MHC/NP
complexes loaded with irrelevant antigens or following
injection of soluble T1D antigens (Fig. 7b) (73). Thus, the
examples in this section underscore the potential of NPs to
deliver drugs and immune signals to alter the interactions of
APCs and lymphocytes in LNs during inﬂammation and
autoimmunity.
Association of Cargo with Biomaterials Can Alter Antigen
Trafficking to Promote Tolerance
Another set of approaches recently harnessed to gener-
ate tolerance with biomaterials exploits the differences in the
mechanisms by which soluble and particulate antigens are
trafﬁcked in LNs and spleens. Whereas relatively low-
molecular-weight soluble antigens are dispersed throughout
SLOs (i.e., LNs, spleen) by the stromal conduits, macro-
phages and other APCs in the SCS engulf and process larger
particles to support presentation of antigenic fragments from
these materials. These differences have been exploited to
promote antigen-speciﬁc tolerance by conjugating 500-nm
polystyrene beads (PSB) or PLGA particles with a myelin
peptide (MYE)—the self-antigen attacked by the immune
system in MS (80,81). Following i.v. injection, antigen-
conjugated particles drained to the spleen and were localized
to macrophages expressing the scavenger receptor MARCO,
whereas free antigen was not (Fig. 8a, b) (80). The MARCO
receptor plays an important role in clearing apoptotic cell
debris—processes that normally occur without inﬂammation.
Thus, PSB-MYE may support presentation of MYE peptide
to APCs in a manner that promotes tolerance (e.g., without
co-stimulation). This idea was supported by studies demon-
strating that antigen-speciﬁc cells in LNs of treated mice
exhibited reduced proliferation when challenged with anti-
gen. Treatment with PSB-MYE formulations also effectively
treated progressive and recurring models of MS in mice,
while treatment with PSBs decorated with irrelevant antigen
(PSB-OVA) did not (Fig. 8c). These ﬁndings illustrate the
antigen-speciﬁc nature of tolerance in this system. Mechanis-
tically, this efﬁcacy resulted from increased TREG function,
along with reductions in activity of inﬂammatory T cells (e.g.,
through anergy/inactivation) (80). These suppressive effects
resulted in reduced lymphocyte inﬁltration to the CNS and
decreased inﬂammatory cytokines (81).
Approaches related to these PSB strategies have also been
applied to other targets such as transplantation and inﬂamma-
tory diseases including colitis, peritonitis, and myocardial
infarction (82,83). Of note are studies with inﬂammatorymodels
using particles exhibiting controlled surface charges but lacking
speciﬁc antigens. These studies have revealed that inﬂammatory
monocytes engulf negatively charged particles and migrate to
the spleen instead of inﬂammation sites, resulting in apoptosis of
these cells and reduced inﬂammation. Interestingly, neutral
particles did not support these therapeutic effects (82). Thus,
this strategy could provide a general, non-antigen-speciﬁc route
for reducing inﬂammation and further underscores the role of
physicochemical properties in determining the types of immune
responses biomaterials elicit. Along these same lines, Broere
and colleagues have shown that the response to antigen
encapsulated in polymers with different carrier structures alters
how LN-resident APCs present and interact with helper T cells
in LNs (84,85). In particular, PLGA NPs and N-trimethyl
Fig. 7. NPs decorated with self-antigen loaded MHC induce DC death and regulate diabetes. a NPs
decorated with MHC molecules speciﬁc to T1D are able to reduce the ratio of CD11c+ DCs in the
pancreatic LN (PLN) to mesenteric LN (MLN) compared to peptide MHC NPs loaded with an irrelevant
antigen. b Mice with T1D treated with NPs conjugated with MHC/diabetes antigen complexes maintain
normal blood glucose levels compared to treatments with soluble peptide or peptide MHC complexes
loaded with irrelevant antigens. Adapted with permission (73)
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chitosan-tri-polyphosphate (TMC-TPP) NPs both increased DC
activation and CD4+ helper T cell proliferation in LNs, but
PLGA promoted regulatory function and reduced
hypersensitivity reactions while TMC-TPP stimulated antibody
responses. Although the mechanisms of these differences are
under investigation, potential contributing factors may include
size (which could alter how antigen is trafﬁcked in LNs) or the
duration over which these particles release antigen (85).
In addition to solid polymer particles encapsulating or
displaying antigen, electrostatically driven condensation of
immune signals such as bacterial DNA affects how these
components are trafﬁcked within LNs. An approach based on
this idea recently revealed that particles formed from
bacterial DNA and poly(ethyleneimine) (PEI), a cationic
polymer, were rapidly trafﬁcked to the follicular and marginal
zones of LNs and the spleen. These complexes stimulated
enzyme pathways that promoted DCs and T cells with
regulatory characteristics, effects not observed when either
PEI or bacterial DNAwas administered alone (86). Together,
the examples highlighted in this subsection illustrate the
potential of designing speciﬁc structures or chemistries into
biomaterials that can help actively direct how NPs and cargos
are trafﬁcked in LNs, as well as to alter the interactions
between LN-resident APCs and lymphocytes.
Biomaterials Can Be Used to Directly Modify Cells to Exploit
Regulatory Immune Pathways
In addition to using particles to transport drugs to LNs or
change how antigens are processed, several recent ap-
proaches have directly modiﬁed APCs, lymphocytes, or red
blood cells with NPs to promote tolerance or regulate
immune response. One group used nanoprecipitation to
prepare particles from PEG and poly(lactide) (PLA) conju-
gated with an immunosuppressant (cyclosporine A (CsA))
(87,88). CsA-loaded particles were phagocytized by DCs
incubated with these carriers in vitro, and subsequent
injection of these DCs into mice resulted in drainage of the
particle-loaded DCs to LNs. These cells locally reduced the
number and proliferative capacity of effector T cells in LNs.
Other approaches have focused on modiﬁcation of T cells
with, for example, NPs decorated with antibodies speciﬁc for
the CD4+ molecules expressed on helper T cells (89). These
particles were loaded with leukemia inhibitory factor
(LIF)—a cytokine that can promote the development of
TREGS—then incubated with donor-reactive cells from the
spleens of mice. CD4-targeted LIF-NPs bound CD4+ T cells
in vitro and transfusion of these cells signiﬁcantly increased
the percentage of TREGS in LNs over 5 days. Thus,
modifying T cells with regulatory immune signals can
serve as a route to deliver cues to LNs that alter how T
cells develop during antigen presentation. This goal of
controlling T cell differentiation shares similarities with the
work of Stephan et al., though their approach aimed to
generate immunostimulatory responses for cancer therapy
by modifying T cells, as discussed earlier (48).
Signiﬁcant fractions of erythrocytes (i.e., red blood cells) are
rapidly produced and destroyed on a daily basis in healthy
individuals. In these cases, cell destruction occurs through a non-
pathogenic mechanism of cell death, apoptosis (90). This
mechanism does not induce pro-inﬂammatory immune responses
against these cells owing to natural regulatory mechanisms that
clear self-antigens without co-stimulation or due to activation of
suppressive pathways triggered by apoptotic cell debris. This
natural tolerance pathway has recently been exploited to generate
antigen-speciﬁc tolerance against model antigens in disease
models of T1D (91). To conduct these studies, a target antigen
(OVA) was conjugated to a peptide (ERY1) that binds
glycophorin-A molecules (GYPA) expressed on the surface of
erythrocytes (Fig. 9a). Ex vivo incubation of ERY1-OVA with
mouse erythrocytes resulted in efﬁcient labeling of these cells with
the target antigen (Fig. 9b, bottom), whereas incubation of
unmodiﬁed OVA with red blood cells did not result in cell
labeling (Fig. 9b, top). Intravenous injection of cargo-modiﬁed
ERY1 (e.g., OVAand ﬂuorescent dye) quickly labeled circulating
erythrocytes and led to increased trafﬁcking to the spleen and
uptake by resident APCs. Mice treated with ERY1-OVA after
injection of OVA-responsive transgenic T cells exhibited reduced
proliferation of these cells in LNs and in the secretion of
inﬂammatory cytokines (e.g., IFN-γ) (Fig. 9c). This idea was also
exploited to protect mice from T1D by stimulating proliferation
and rapid deletion of self-reactive CD4+ Tcells in LNs whenmice
were treated with ERY1 conjugated to T1D antigens, but not
when soluble T1D antigens were administered. Together, these
approaches demonstrate that a diverse set of cell modiﬁcation
approaches can alter how APCs and T cells function, as well as
harness natural apoptotic clearance and tolerance mechanisms to
regulate or redirect inﬂammatory immune reactions.
Fig. 8. Particles targeting the MARCO receptor induce tolerance against a mouse model of multiple sclerosis. a
Immunohistochemical staining of spleens following intravenous injection of polystyrene particles conjugated with a myelin
peptide (PSB-MYE, green) showing co-localization of particles with MARCO (red). b Immunohistochemical staining as in a
of spleen after treatment without polystyrene particles (no PSB). c Disease severity following immunization with PSB-MYE
or polystyrene particles conjugated with an irrelevant peptide (PSB-OVA) showing that antigen speciﬁcity is necessary for
treatment. Adapted with permission (80)
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CONCLUSIONS AND LOOKING FORWARD
Biomaterials have already demonstrated great potential
in the ﬁeld of immunology. In coming years, continuing to
improve our understanding of how material properties impact
molecular signaling will remain an important issue, as this
knowledge will lead to more rational design of vaccines.
Employing biomaterials as tools to study new fundamental
questions will also provide new opportunities to inform
vaccine and immunotherapy design. An exciting avenue of
research centers on engineering biomaterials with speciﬁc
properties that allow for precise interactions with LNs and
LN-resident cell populations that effectively modify the
structure of these tissues. Some of these questions may also
focus on understanding how the kinetics and combinations of
immune signals in LNs impact stromal function (e.g., FRC
network, laminins), and if these changes can be induced or
exploited to direct immunity. Another interesting approach
on the horizon is the design of artiﬁcial LNs or SLOs that
could locally recapitulate the functions of these tissues,
perhaps eliminating the targeting challenges facing many
vaccines and treatments. Biomaterials offer unique opportu-
nities to address each of these areas, and the answers to these
questions will continue to push the forefront of what may
become possible in modulating immune function.
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